Clinical Trials Browser

Phase 1/2 × Recurrence × ublituximab × Clear all

NCT01647971 2022-11-21

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone